The last patient has been enrolled in the company’s study for the localized treatment of prostate cancer.
The Phase IIb study will identify the optimal dose for Phase III and test the safety of Liproca Depot and its effectiveness in stopping cancer progression. Liproca Depot is based on LIDDS NanoZolid drug delivery technology.
“We are very pleased that patient recruitment is now finalized and we look forward to concluding the study and receiving the results in third quarter this year,” says Monica Wallter, CEO of LIDDS. “We expect this study to show that by injecting Liproca Depot directly into the tumor, prostate cancer progression can be stopped and patients can avoid radical surgery and radiation therapy which are associated with side effects such as sexual dysfunction and incontinence. A large prostate cancer patient group is currently not receiving any treatment and Liproca Depot has the potential to provide a new treatment regimen that will benefit healthcare providers and prostate cancer sufferers in a market worth over USD 9 billion annually.”
The Phase IIb study for Liproca Depot includes 60 patients and is being conducted at major urology clinics in Canada, Finland and Lithuania.
Agreement in China
LIDDS has already signed an exclusive licensing agreement for Liproca Depot in China with the Puheng Jiangxi pharmaceutical company. Preparations are ongoing in China for a Phase III clinical study that will be fully funded by the Chinese licensee. Prostate cancer is a very common disease in China and around 500 000 patients are diagnosed each year.
“We look forward to continuing our dialogue with major pharmaceutical companies on out-licensing Liproca Depot in the US, Europe and the rest of the world. With more than USD 3 billion currently being spent each year on localized prostate cancer treatment, Liproca Depot can offer a new regimen that benefits patients, healthcare providers and pharmaceutical companies,” says Monica Wallter.